{"id":{"repo_id":"uab","oai_identifier":"oai:digitalcommons.library.uab.edu:etd-collection-8331"},"canonical_url":"https://search.ndltd.org/etd/uab/oai:digitalcommons.library.uab.edu:etd-collection-8331","repository":{"repo_id":"uab","name":"University of Alabama Birmingham","base_url":"https://digitalcommons.library.uab.edu/do/oai/"},"display":{"title":"Mechanism Of Targeted Cancer Therapeutics-Induced Cardiotoxicity","abstract":"Targeted cancer therapies are known to cause cardiovascular (CV) complications in human patients. Agents such as osimertinib, a tyrosine kinase inhibitor (TKI), as well as immune checkpoint inhibitors (ICIs) have been demonstrated to induce severe cardiotoxicities, including heart failure and myocarditis. Nevertheless, the mechanisms of TKIs and ICIs-induced cardiotoxicity remain poorly understood. Herein, we developed the first in vivo preclinical model of osimertinib-induced cardiotoxicity using a transverse aortic constriction (TAC) mouse model. Osimertinib-treated mice displayed severe cardiac dysfunction, elevated markers of heart failure and fibrosis, and failed to undergo compensatory hypertrophic remodeling, resulting in cardiomyocyte death. Mechanistically, we identified suppression of ERK/AKT prosurvival signaling, mitochondrial dysfunction, and activation of Bax/Bcl-xl apoptosis pathway. FDA-approved HDAC inhibitor Vorinostat (SAHA), restored cardiac function and cell survival while improving osimertinib’s efficacy in non-small cell lung cancer (NSCLC)-derived PC9 cells. In a separate set of studies, we examined ICIs-associated myocarditis employing a myeloid-specific programmed death-ligand (PD-L1) knockout (KO) mice. Deletion of PD-L1 led to early-onset cardiac dysfunction, systemic inflammation, increased infiltration of CCR2+ pro-inflammatory macrophages, and enhanced T cell activation, revealing a critical immunoregulatory role for myeloid PD-L1 in maintaining cardiac homeostasis. Our findings define the mechanisms of cardiotoxicity induced by targeted therapies and highlight histone deacetylase (HDAC) inhibitions and myeloid-specific immune modulation as potential targeted strategies to mitigate treatment-related cardiac events.","abstract_html":"Targeted cancer therapies are known to cause cardiovascular (CV) complications in human patients. Agents such as osimertinib, a tyrosine kinase inhibitor (TKI), as well as immune checkpoint inhibitors (ICIs) have been demonstrated to induce severe cardiotoxicities, including heart failure and myocarditis. Nevertheless, the mechanisms of TKIs and ICIs-induced cardiotoxicity remain poorly understood. Herein, we developed the first in vivo preclinical model of osimertinib-induced cardiotoxicity using a transverse aortic constriction (TAC) mouse model. Osimertinib-treated mice displayed severe cardiac dysfunction, elevated markers of heart failure and fibrosis, and failed to undergo compensatory hypertrophic remodeling, resulting in cardiomyocyte death. Mechanistically, we identified suppression of ERK/AKT prosurvival signaling, mitochondrial dysfunction, and activation of Bax/Bcl-xl apoptosis pathway. FDA-approved HDAC inhibitor Vorinostat (SAHA), restored cardiac function and cell survival while improving osimertinib’s efficacy in non-small cell lung cancer (NSCLC)-derived PC9 cells. In a separate set of studies, we examined ICIs-associated myocarditis employing a myeloid-specific programmed death-ligand (PD-L1) knockout (KO) mice. Deletion of PD-L1 led to early-onset cardiac dysfunction, systemic inflammation, increased infiltration of CCR2+ pro-inflammatory macrophages, and enhanced T cell activation, revealing a critical immunoregulatory role for myeloid PD-L1 in maintaining cardiac homeostasis. Our findings define the mechanisms of cardiotoxicity induced by targeted therapies and highlight histone deacetylase (HDAC) inhibitions and myeloid-specific immune modulation as potential targeted strategies to mitigate treatment-related cardiac events.","abstract_has_math":false,"creators":["Toro-Cora, Angelica"],"institution":null,"degree_name":"Doctor of Philosophy (PhD)","degree_level":"Dissertation","degree_discipline":"Cellular and Molecular Physiology","degree_department":null,"school":null,"contributors":["<p>Hind Lal</p>"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T09:28:56Z","subjects":[],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://digitalcommons.library.uab.edu/etd-collection/7339","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://digitalcommons.library.uab.edu/etd-collection/7339","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://digitalcommons.library.uab.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Adigitalcommons.library.uab.edu%3Aetd-collection-8331","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["<p>Hind Lal</p>"]},{"key":"dc:creator","label":"Author","values":["Toro-Cora, Angelica"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.created","label":"Dc Date Created","values":["2025-09-11T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Cellular and Molecular Physiology"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy (PhD)"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://digitalcommons.library.uab.edu/etd-collection/7339"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Targeted cancer therapies are known to cause cardiovascular (CV) complications in human patients. Agents such as osimertinib, a tyrosine kinase inhibitor (TKI), as well as immune checkpoint inhibitors (ICIs) have been demonstrated to induce severe cardiotoxicities, including heart failure and myocarditis. Nevertheless, the mechanisms of TKIs and ICIs-induced cardiotoxicity remain poorly understood. Herein, we developed the first in vivo preclinical model of osimertinib-induced cardiotoxicity using a transverse aortic constriction (TAC) mouse model. Osimertinib-treated mice displayed severe cardiac dysfunction, elevated markers of heart failure and fibrosis, and failed to undergo compensatory hypertrophic remodeling, resulting in cardiomyocyte death. Mechanistically, we identified suppression of ERK/AKT prosurvival signaling, mitochondrial dysfunction, and activation of Bax/Bcl-xl apoptosis pathway. FDA-approved HDAC inhibitor Vorinostat (SAHA), restored cardiac function and cell survival while improving osimertinib’s efficacy in non-small cell lung cancer (NSCLC)-derived PC9 cells. In a separate set of studies, we examined ICIs-associated myocarditis employing a myeloid-specific programmed death-ligand (PD-L1) knockout (KO) mice. Deletion of PD-L1 led to early-onset cardiac dysfunction, systemic inflammation, increased infiltration of CCR2+ pro-inflammatory macrophages, and enhanced T cell activation, revealing a critical immunoregulatory role for myeloid PD-L1 in maintaining cardiac homeostasis. Our findings define the mechanisms of cardiotoxicity induced by targeted therapies and highlight histone deacetylase (HDAC) inhibitions and myeloid-specific immune modulation as potential targeted strategies to mitigate treatment-related cardiac events."]},{"key":"dc:title","label":"Title","values":["Mechanism Of Targeted Cancer Therapeutics-Induced Cardiotoxicity"]}]}],"canonical_facts":{"dc:contributor":["<p>Hind Lal</p>"],"dc:creator":["Toro-Cora, Angelica"],"dc:date.created":["2025-09-11T07:00:00Z"],"dc:description.abstract":["Targeted cancer therapies are known to cause cardiovascular (CV) complications in human patients. Agents such as osimertinib, a tyrosine kinase inhibitor (TKI), as well as immune checkpoint inhibitors (ICIs) have been demonstrated to induce severe cardiotoxicities, including heart failure and myocarditis. Nevertheless, the mechanisms of TKIs and ICIs-induced cardiotoxicity remain poorly understood. Herein, we developed the first in vivo preclinical model of osimertinib-induced cardiotoxicity using a transverse aortic constriction (TAC) mouse model. Osimertinib-treated mice displayed severe cardiac dysfunction, elevated markers of heart failure and fibrosis, and failed to undergo compensatory hypertrophic remodeling, resulting in cardiomyocyte death. Mechanistically, we identified suppression of ERK/AKT prosurvival signaling, mitochondrial dysfunction, and activation of Bax/Bcl-xl apoptosis pathway. FDA-approved HDAC inhibitor Vorinostat (SAHA), restored cardiac function and cell survival while improving osimertinib’s efficacy in non-small cell lung cancer (NSCLC)-derived PC9 cells. In a separate set of studies, we examined ICIs-associated myocarditis employing a myeloid-specific programmed death-ligand (PD-L1) knockout (KO) mice. Deletion of PD-L1 led to early-onset cardiac dysfunction, systemic inflammation, increased infiltration of CCR2+ pro-inflammatory macrophages, and enhanced T cell activation, revealing a critical immunoregulatory role for myeloid PD-L1 in maintaining cardiac homeostasis. Our findings define the mechanisms of cardiotoxicity induced by targeted therapies and highlight histone deacetylase (HDAC) inhibitions and myeloid-specific immune modulation as potential targeted strategies to mitigate treatment-related cardiac events."],"dc:identifier":["https://digitalcommons.library.uab.edu/etd-collection/7339"],"dc:title":["Mechanism Of Targeted Cancer Therapeutics-Induced Cardiotoxicity"],"thesis:degree_discipline":["Cellular and Molecular Physiology"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Doctor of Philosophy (PhD)"]},"updated_at":"2026-11-19T09:28:56Z"}